Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants: Study protocol for a randomised controlled trial

Smita Awasthi, Reason Wilken, Forum Patel, J. Bruce German, David A. Mills, Carlito B Lebrilla, Kyoungmi Kim, Samara L. Freeman, Jennifer T. Smilowitz, April W. Armstrong, Emanual Michael Maverakis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The development of probiotics as therapies to cure or prevent disease lags far behind that of other investigational medications. Rigorously designed phase I clinical trials are nearly non-existent in the field of probiotic research, which is a contributing factor to this disparity. As a consequence, how to appropriately dose probiotics to study their efficacy is unknown. Herein we propose a novel phase I ascending dose trial of Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut colonisation in healthy breastfed infants at 6 weeks of age. Methods/design: This is a parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I clinical trial of dietary supplementation with B. infantis in healthy breastfed infants. The objective is to determine the pharmacologically effective dose (ED) of B. infantis required to produce predominant (>50 %) gut colonisation in breastfed infants at 6 weeks of age. Successively enrolled infant groups will be randomised to receive two doses of either B. infantis or placebo on days 7 and 14 of life. Stool samples will be used to characterise the gut microbiota at increasing doses of B. infantis. Discussion: Probiotic supplementation has shown promising results for the treatment of a variety of ailments, but evidence-based dosing regimes are currently lacking. The ultimate goal of this trial is to establish a recommended starting dose of B. infantis for further efficacy-testing phase II trials designed to evaluate B. infantis for the prevention of atopic dermatitis and food allergies in at-risk children. Trial registration: Clinicaltrials.gov #NCT02286999 , date of trial registration 23 October 2014.

Original languageEnglish (US)
Article number340
JournalTrials
Volume17
Issue number1
DOIs
StatePublished - Jul 22 2016

Fingerprint

Probiotics
Dietary Supplements
Randomized Controlled Trials
Clinical Trials, Phase I
Placebos
Food Hypersensitivity
Atopic Dermatitis
Bifidobacterium longum
Therapeutics
Research

Keywords

  • Atopic dermatitis
  • Atopy
  • Bifidobacterium infantis
  • Dose-escalation
  • Food allergy
  • Phase I clinical trial
  • Probiotic

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants : Study protocol for a randomised controlled trial. / Awasthi, Smita; Wilken, Reason; Patel, Forum; German, J. Bruce; Mills, David A.; Lebrilla, Carlito B; Kim, Kyoungmi; Freeman, Samara L.; Smilowitz, Jennifer T.; Armstrong, April W.; Maverakis, Emanual Michael.

In: Trials, Vol. 17, No. 1, 340, 22.07.2016.

Research output: Contribution to journalArticle

Awasthi, Smita ; Wilken, Reason ; Patel, Forum ; German, J. Bruce ; Mills, David A. ; Lebrilla, Carlito B ; Kim, Kyoungmi ; Freeman, Samara L. ; Smilowitz, Jennifer T. ; Armstrong, April W. ; Maverakis, Emanual Michael. / Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants : Study protocol for a randomised controlled trial. In: Trials. 2016 ; Vol. 17, No. 1.
@article{e85a41f4059440399bb4385d253514e5,
title = "Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants: Study protocol for a randomised controlled trial",
abstract = "Background: The development of probiotics as therapies to cure or prevent disease lags far behind that of other investigational medications. Rigorously designed phase I clinical trials are nearly non-existent in the field of probiotic research, which is a contributing factor to this disparity. As a consequence, how to appropriately dose probiotics to study their efficacy is unknown. Herein we propose a novel phase I ascending dose trial of Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut colonisation in healthy breastfed infants at 6 weeks of age. Methods/design: This is a parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I clinical trial of dietary supplementation with B. infantis in healthy breastfed infants. The objective is to determine the pharmacologically effective dose (ED) of B. infantis required to produce predominant (>50 {\%}) gut colonisation in breastfed infants at 6 weeks of age. Successively enrolled infant groups will be randomised to receive two doses of either B. infantis or placebo on days 7 and 14 of life. Stool samples will be used to characterise the gut microbiota at increasing doses of B. infantis. Discussion: Probiotic supplementation has shown promising results for the treatment of a variety of ailments, but evidence-based dosing regimes are currently lacking. The ultimate goal of this trial is to establish a recommended starting dose of B. infantis for further efficacy-testing phase II trials designed to evaluate B. infantis for the prevention of atopic dermatitis and food allergies in at-risk children. Trial registration: Clinicaltrials.gov #NCT02286999 , date of trial registration 23 October 2014.",
keywords = "Atopic dermatitis, Atopy, Bifidobacterium infantis, Dose-escalation, Food allergy, Phase I clinical trial, Probiotic",
author = "Smita Awasthi and Reason Wilken and Forum Patel and German, {J. Bruce} and Mills, {David A.} and Lebrilla, {Carlito B} and Kyoungmi Kim and Freeman, {Samara L.} and Smilowitz, {Jennifer T.} and Armstrong, {April W.} and Maverakis, {Emanual Michael}",
year = "2016",
month = "7",
day = "22",
doi = "10.1186/s13063-016-1467-1",
language = "English (US)",
volume = "17",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants

T2 - Study protocol for a randomised controlled trial

AU - Awasthi, Smita

AU - Wilken, Reason

AU - Patel, Forum

AU - German, J. Bruce

AU - Mills, David A.

AU - Lebrilla, Carlito B

AU - Kim, Kyoungmi

AU - Freeman, Samara L.

AU - Smilowitz, Jennifer T.

AU - Armstrong, April W.

AU - Maverakis, Emanual Michael

PY - 2016/7/22

Y1 - 2016/7/22

N2 - Background: The development of probiotics as therapies to cure or prevent disease lags far behind that of other investigational medications. Rigorously designed phase I clinical trials are nearly non-existent in the field of probiotic research, which is a contributing factor to this disparity. As a consequence, how to appropriately dose probiotics to study their efficacy is unknown. Herein we propose a novel phase I ascending dose trial of Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut colonisation in healthy breastfed infants at 6 weeks of age. Methods/design: This is a parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I clinical trial of dietary supplementation with B. infantis in healthy breastfed infants. The objective is to determine the pharmacologically effective dose (ED) of B. infantis required to produce predominant (>50 %) gut colonisation in breastfed infants at 6 weeks of age. Successively enrolled infant groups will be randomised to receive two doses of either B. infantis or placebo on days 7 and 14 of life. Stool samples will be used to characterise the gut microbiota at increasing doses of B. infantis. Discussion: Probiotic supplementation has shown promising results for the treatment of a variety of ailments, but evidence-based dosing regimes are currently lacking. The ultimate goal of this trial is to establish a recommended starting dose of B. infantis for further efficacy-testing phase II trials designed to evaluate B. infantis for the prevention of atopic dermatitis and food allergies in at-risk children. Trial registration: Clinicaltrials.gov #NCT02286999 , date of trial registration 23 October 2014.

AB - Background: The development of probiotics as therapies to cure or prevent disease lags far behind that of other investigational medications. Rigorously designed phase I clinical trials are nearly non-existent in the field of probiotic research, which is a contributing factor to this disparity. As a consequence, how to appropriately dose probiotics to study their efficacy is unknown. Herein we propose a novel phase I ascending dose trial of Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut colonisation in healthy breastfed infants at 6 weeks of age. Methods/design: This is a parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I clinical trial of dietary supplementation with B. infantis in healthy breastfed infants. The objective is to determine the pharmacologically effective dose (ED) of B. infantis required to produce predominant (>50 %) gut colonisation in breastfed infants at 6 weeks of age. Successively enrolled infant groups will be randomised to receive two doses of either B. infantis or placebo on days 7 and 14 of life. Stool samples will be used to characterise the gut microbiota at increasing doses of B. infantis. Discussion: Probiotic supplementation has shown promising results for the treatment of a variety of ailments, but evidence-based dosing regimes are currently lacking. The ultimate goal of this trial is to establish a recommended starting dose of B. infantis for further efficacy-testing phase II trials designed to evaluate B. infantis for the prevention of atopic dermatitis and food allergies in at-risk children. Trial registration: Clinicaltrials.gov #NCT02286999 , date of trial registration 23 October 2014.

KW - Atopic dermatitis

KW - Atopy

KW - Bifidobacterium infantis

KW - Dose-escalation

KW - Food allergy

KW - Phase I clinical trial

KW - Probiotic

UR - http://www.scopus.com/inward/record.url?scp=84979084540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979084540&partnerID=8YFLogxK

U2 - 10.1186/s13063-016-1467-1

DO - 10.1186/s13063-016-1467-1

M3 - Article

C2 - 27449926

AN - SCOPUS:84979084540

VL - 17

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 340

ER -